New results from an ongoing clinical trial provide strong evidence that emergency departments can safely start buprenorphine treatment for opioid use disorder without triggering withdrawal in people who use fentanyl, the National Institutes of Health reports. The findings build upon existing evidence that administering buprenorphine in emergency departments helps people begin addiction treatment and that higher-dose buprenorphine is safe and well tolerated in people with OUD experiencing withdrawal symptoms, the agency said.
 
“The emergency department is an important touchpoint for providing life-saving medication and resources for people at risk for overdose,” said Rebecca Baker, director of NIH’s Helping to End Addiction Long-term Initiative. “We need to meet people where they are amid an increasingly deadly overdose crisis.” 

Related News Articles

Headline
The AHA Dec. 7 sent a letter supporting the Support for Patients and Communities Reauthorization Act (H.R. 4531), bipartisan legislation that would reauthorize…
Headline
The Centers for Disease Control and Prevention recently awarded $279 million to help state and local health departments respond to the drug overdose…
Headline
Pregnant people with opioid use disorder are more likely to receive buprenorphine (a recommended treatment) if they are older, white and have public insurance…
Headline
Medicare patients who have access to telehealth services and medications for opioid use disorder have lower risk of fatal drug overdose, according to a study…
Headline
The Food and Drug Administration yesterday issued a report offering recommendations to address the opioid crisis and the role of analgesic oversight in…
Headline
The share of U.S. overdose deaths involving buprenorphine did not increase after federal agencies allowed clinicians to prescribe the opioid use disorder…